

REVISION OF FY2021 FORECASTS

(Year ending March 31, 2022)



Nippon Chemiphar Co., Ltd. (4539)
January 31, 2022

Reflecting recent business performance, Nippon Chemiphar Co., Ltd. has revised its forecasts issued on May 14, 2021.

Revised: Consolidated Forecasts for FY2021 (April 1, 2021–March 31, 2022)

	Net Sales (¥mn)	Operating Income (¥mn)	Net Income attributable to owners of the parent (¥mn)	Earnings per Share (¥)
Previous forecast (A)	31,000	350	80	22.25
Revision (B)	32,000	600	400	110.95
Change (B - A)	1,000	250	320	
% change	3.2	71.4	400.0	
FY2020 results	31,541	564	495	137.75

Reasons for revisions

Net sales, operating income and net income forecasts have been revised up thanks in part to strong sales of generic drugs launched in FY2020 and June 2021; to an increase in demand stemming from quality issues at other companies that manufacture and sell generic drugs.

* The forecasts are based on currently available information, but the figures may change to reflect future conditions, thus causing results to differ.

For further information contact:
Public Relations Department, Nippon Chemiphar Co., Ltd.
e-mail: ir@chemiphar.co.jp